TY  - GEN
AU  - Mooi,J K
AU  - Wirapati,P
AU  - Asher,R
AU  - Lee,C K
AU  - Savas,P
AU  - Price,T J
AU  - Townsend,A
AU  - Hardingham,J
AU  - Buchanan,D
AU  - Williams,D
AU  - Tejpar,S
AU  - Mariadason,J M
AU  - Tebbutt,N C
TI  - The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
SN  - 1569-8041
PY  - 2019///1113
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - Capecitabine
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Female
KW  - Gene Expression Profiling
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Mitomycin
KW  - Prognosis
KW  - Progression-Free Survival
KW  - Transcriptome
KW  - genetics
N1  - Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy410
ER  -